Genomewide association for schizophrenia in the CATIE study: Results of stage 1

P. F. Sullivan, D. Lin, J. Y. Tzeng, E. Van Den Oord, D. Perkins, T. S. Stroup, M. Wagner, S. Lee, F. A. Wright, F. Zou, W. Liu, A. M. Downing, J. Lieberman, S. L. Close

研究成果: Article同行評審

295 引文 斯高帕斯(Scopus)


Little is known for certain about the genetics of schizophrenia. The advent of genomewide association has been widely anticipated as a promising means to identify reproducible DNA sequence variation associated with this important and debilitating disorder. A total of 738 cases with DSM-IV schizophrenia (all participants in the CATIE study) and 733 group-matched controls were genotyped for 492 900 single-nucleotide polymorphisms (SNPs) using the Affymetrix 500K two-chip genotyping platform plus a custom 164K fill-in chip. Following multiple quality control steps for both subjects and SNPs, logistic regression analyses were used to assess the evidence for association of all SNPs with schizophrenia. We identified a number of promising SNPs for follow-up studies, although no SNP or multimarker combination of SNPs achieved genomewide statistical significance. Although a few signals coincided with genomic regions previously implicated in schizophrenia, chance could not be excluded. These data do not provide evidence for the involvement of any genomic region with schizophrenia detectable with moderate sample size. However, a planned genomewide association study for response phenotypes and inclusion of individual phenotype and genotype data from this study in meta-analyses hold promise for eventual identification of susceptibility and protective variants.

頁(從 - 到)570-584
期刊Molecular Psychiatry
出版狀態Published - 2008 6月

All Science Journal Classification (ASJC) codes

  • 分子生物學
  • 細胞與分子神經科學
  • 精神病學和心理健康


深入研究「Genomewide association for schizophrenia in the CATIE study: Results of stage 1」主題。共同形成了獨特的指紋。